Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports its attendance at the MipTec 2012 Conference in Basel, Switzerland.
A leading European event focusing on drug discovery, the MipTec Conference brings together leading industry experts and academics from all over the world to discuss new technologies and to network. Commenting on his experience of the conference, Dr Salman Rahman the CEO and co-founder of Vasgen said: ”Apart from learning about the latest developments in biomedical drug discovery, the MipTec Conference was an excellent opportunity for Vasgen to interact with both small to medium-sized biotech companies and big pharma. We had the opportunity to discuss the Company’s technology and lead programme with a number of industry leaders who provided plenty of positive feedback. Overall, attending MipTec was a valuable learning experience and we hope to be there again next year.”
-Ends-
Notes to Editors
Vasgen limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs. The Company’s technologies include AbIMPTM, a novel antibody-based approach allowing development of highly selective inhibitors of metalloproteinase catalytic activity with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk
For further information please contact:
Tel : +44 (0)207 691 2149